Ramachandra et al. showed that MDSCs can protect MM cells from chemotherapy reagents, doxorubicin and melphalan; and, interestingly, this effect is mediated by soluble factors, such as IL-6 [180]. The gene discussed is IL6; the disease is Miyoshi myopathy.